Related Experiment Video
Updated: May 8, 2026

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
Published on: August 24, 2019
Chronic ulcerative colitis and colorectal cancer
1Division of Gastroenterology and Hepatology, Department of Visceral Medicine, University Hospital Zürich, Rämistrasse 100, CH-8091 Zürich, Switzerland.
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), significantly increases colorectal cancer (CRC) risk. Colitis-associated CRC (CAC) has a distinct pathophysiology, differing from sporadic CRC, with unique genetic mutations and potential microbiome involvement.
Area of Science:
- Gastroenterology
- Oncology
- Molecular Biology
Background:
- Chronic inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), is a major risk factor for colorectal cancer (CRC).
- Colitis-associated CRC (CAC) exhibits a different pathophysiology and genetic mutation profile compared to sporadic CRC.
- Chronic inflammation, epithelial cell turnover, reactive oxygen species (ROS), and potentially the gut microbiome contribute to CAC development.
Purpose of the Study:
- To elucidate the distinct pathophysiology of colitis-associated colorectal cancer (CAC) compared to sporadic CRC.
- To identify key genetic mutations and molecular pathways involved in CAC development.
- To highlight the clinical implications and treatment strategies for CAC in IBD patients.
Main Methods:
- Review of existing literature on IBD, CRC, and CAC.
- Comparative analysis of genetic mutations and molecular pathways in sporadic CRC versus CAC.
- Discussion of the role of inflammation, ROS, and the microbiome in CAC pathogenesis.
Main Results:
- CAC does not follow the typical adenoma-carcinoma sequence seen in sporadic CRC.
- Mutations in p53 and K-ras occur earlier in CAC, while APC mutations are often late-stage.
- Wnt/β-catenin pathway mutations are less common in CAC compared to sporadic CRC.
- CAC often presents with aggressive growth and early metastasis.
Conclusions:
- CAC development is driven by chronic inflammation and distinct genetic alterations.
- The intestinal microbiome may play a significant role in CAC pathogenesis.
- Proctocolectomy with ileoanal anastomosis is the standard treatment for CAC in IBD patients due to frequent metachronous lesions.
Related Concept Videos
Inflammatory Bowel Disease II: Ulcerative Colitis
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease I: Introduction
Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...

